Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) Research & Development (2018 - 2025)

Abvc Biopharma (ABVC) has disclosed Research & Development for 10 consecutive years, with $29058.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 9.14% year-over-year to $29058.0, compared with a TTM value of $121085.0 through Dec 2025, down 32.46%, and an annual FY2025 reading of $121085.0, down 32.46% over the prior year.
  • Research & Development was $29058.0 for Q4 2025 at Abvc Biopharma, down from $29890.0 in the prior quarter.
  • Across five years, Research & Development topped out at $1.5 million in Q4 2022 and bottomed at $28861.0 in Q1 2025.
  • Average Research & Development over 5 years is $253026.8, with a median of $131312.5 recorded in 2021.
  • The sharpest move saw Research & Development skyrocketed 474.89% in 2022, then crashed 95.17% in 2023.
  • Year by year, Research & Development stood at $260188.0 in 2021, then surged by 474.89% to $1.5 million in 2022, then plummeted by 95.17% to $72185.0 in 2023, then tumbled by 55.7% to $31980.0 in 2024, then dropped by 9.14% to $29058.0 in 2025.
  • Business Quant data shows Research & Development for ABVC at $29058.0 in Q4 2025, $29890.0 in Q3 2025, and $33276.0 in Q2 2025.